Juq-063 | ^hot^

Title: Beyond the Frame: Deconstructing Narrative, Aesthetic, and Subtext in JUQ-063

4. Clinical Development Program

| Phase | Trial ID | Design | Population | Primary Endpoint | Status (as of Apr 2026) | |-------|----------|--------|------------|------------------|------------------------| | Phase I | NCT05873201 | Open‑label, dose escalation (3 + 3) → RP2D identification | Advanced solid tumors harboring KRAS G12D (PDAC, CRC, NSCLC) | Safety, MTD, PK/PD, ORR (exploratory) | Completed (2025); RP2D = 30 mg QD | | Phase Ib/IIa | NCT05984212 | Cohort expansion + pembrolizumab combo (PD‑1 blockade) | KRAS G12D‑mutant PDAC, previously treated | ORR, DCR, PFS (12‑wk) | Ongoing (enrollment 70 % complete) | | Phase IIb | NCT06000123 | Randomized (1:1) JUQ‑063 + standard gemcitabine/nab‑paclitaxel vs. standard chemo alone | Treatment‑naïve KRAS G12D PDAC | PFS, OS, safety | Initiated Q3 2025 | | Phase III (Planned) | NCT06123456 | Global, double‑blind, JUQ‑063 + chemo ± immunotherapy vs. chemo + immunotherapy | Metastatic KRAS G12D PDAC | OS (primary), PFS, QoL | Protocol development 2026, IND filing Q4 2026 | JUQ-063

Title: JUQ-063: Pioneering Innovation in Advanced Energy Systems
Subtitle: A Deep Dive into the Revolutionary Hybrid Energy Grid Transformer chemo + immunotherapy | Metastatic KRAS G12D PDAC

Eat normally for five days a week and restrict calories (around 500–600) on the other two days. Eat-Stop-Eat: A full 24-hour fast once or twice a week. 2. Fasting Window Essentials Fasting Window Essentials